| Methods |
Allocation: randomised
Blinding: double blind
Design: parallel study
Sample size at entry: Auranofin 10; GSTM 11, placebo 11
Analysis: completers 85.7% (auranofin 10, placebo 8) |
| Participants |
Country: UK
Patients with active RA (early, mild disease)
Age: mean 53.3 yr
Duration of disease: mean 3.02 yr
Females: 72%
RF: not reported
Concomitant use of steroids or other DMARD: none
Previous use of DMARDS or steroids: none |
| Interventions |
Auranofin 6m g/day, GSTM IM 50 mg/wk or placebo
Treatment duration: 12 mo, 9 m data reported |
| Outcomes |
Tender joints: Ritchie index
Pain VAS |
| Notes |
Quality score: 4
Allocation concealment: unclear
Group using GSTM not included in analysis
Reported: baseline & end of trial values. Imputed 12 mo SD to 9 mo data for Ritchie index
Withdrawals at six mo. reported
ADR results reported at 9 months. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
